Clinical study on low-dose rituximab maintenance therapy in children with primary nephrotic syndrome

Wen-Ting PENG; Xiao-Zhong LI

doi:10.7499/j.issn.1008-8830.2409131

PDF(665 KB)

Chinese Journal of Contemporary Pediatrics ›› 2025, Vol. 27 ›› Issue (8) : 982-988. DOI: 10.7499/j.issn.1008-8830.2409131

CLINICAL RESEARCH

Clinical study on low-dose rituximab maintenance therapy in children with primary nephrotic syndrome

Wen-Ting PENG ¹^,² ,
Xiao-Zhong LI ²

Author information +

History +

Abstract

Objective To investigate the clinical efficacy and safety of low-dose rituximab (RTX) (<375 mg/m²) maintenance therapy in children with primary nephrotic syndrome (PNS). Methods A retrospective analysis was conducted on the clinical data of PNS children who received low-dose RTX therapy at the Department of Renal Immunology, Children's Hospital of Soochow University from July 2016 to March 2024. Remission rate, recurrence frequency, corticosteroid and tacrolimus usage, and adverse reactions before and after RTX treatment were analyzed. Results Compared with before treatment, low-dose RTX maintained remission in PNS, reduced the relapse frequency, and decreased the dosage of corticosteroids and tacrolimus (P<0.05). IgG levels did not significantly decrease, and no additional preventive anti-infective treatment was required. Conclusions Low-dose RTX therapy is effective and safe for treating PNS in children.

Key words

Primary nephrotic syndrome / Low dose / Rituximab / Child

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations

Wen-Ting PENG , Xiao-Zhong LI. Clinical study on low-dose rituximab maintenance therapy in children with primary nephrotic syndrome[J]. Chinese Journal of Contemporary Pediatrics. 2025, 27(8): 982-988 https://doi.org/10.7499/j.issn.1008-8830.2409131

References

List( Publishing order | Descend order by publishing year | Descend order by cited within ) Chart analysis

[1]	中华医学会儿科学分会肾脏学组. 儿童激素敏感、复发/依赖肾病综合征诊治循证指南（2016）[J]. 中华儿科杂志, 2017, 55(10): 729-734. DOI: 10.3760/cma.j.issn.0578-1310.2017.10.003 . https://www.ncbi.nlm.nih.gov/pubmed/29050108 Cited in this article [3]

[2]

Trautmann

, Boyer

, Hodson

, et al. IPNA clinical practice recommendations for the diagnosis and management of children with steroid-sensitive nephrotic syndrome[J]. Pediatr Nephrol, 2023, 38(3): 877-919. PMCID: PMC9589698. DOI: 10.1007/s00467-022-05739-3 .

https://www.ncbi.nlm.nih.gov/pubmed/36269406

Cited in this article [1]

[3]

Disease

Kidney

: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. KDIGO 2021 clinical practice guideline for the management of glomerular diseases[J]. Kidney Int, 2021, 100(4S): S1-S276. DOI: 10.1016/j.kint.2021.05.021 .

https://www.ncbi.nlm.nih.gov/pubmed/34556256

Cited in this article [1]

[4]	Croitoru A, Balgradean M. Treatment-associated side effects in patients with steroid-dependent nephrotic syndrome[J]. Maedica (Bucur), 2022, 17(2): 285-290. PMCID: PMC9375867. DOI: 10.26574/maedica.2022.17.2.285 . https://www.ncbi.nlm.nih.gov/pubmed/36032609 Cited in this article [1]

[5]

Nagai

. Immunosuppressive agent options for primary nephrotic syndrome: a review of network meta-analyses and cost-effectiveness analysis[J]. Medicina (Kaunas), 2023, 59(3): 601. PMCID: PMC10054564. DOI: 10.3390/medicina59030601 .

https://www.ncbi.nlm.nih.gov/pubmed/36984602

Cited in this article [1]

[6]	Horinouchi T, Nozu K, Iijima K. An updated view of the pathogenesis of steroid-sensitive nephrotic syndrome[J]. Pediatr Nephrol, 2022, 37(9): 1957-1965. PMCID: PMC9307535. DOI: 10.1007/s00467-021-05401-4 . https://www.ncbi.nlm.nih.gov/pubmed/35006356 Cited in this article [1]

[7]	中华医学会肾脏病学分会专家组. 利妥昔单抗在肾小球肾炎中应用的专家共识[J]. 中华肾脏病杂志, 2022, 38(2): 151-160. DOI: 10.3760/cma.j.cn441217-20210615-00023 . Cited in this article [1]

[8]	利妥昔单抗在儿童激素敏感型肾病综合征中应用临床实践指南工作组. 利妥昔单抗在儿童激素敏感型肾病综合征中应用临床实践指南[J]. 中国循证儿科杂志, 2023, 18(4): 245-254. DOI: 10.3969/j.issn.1673-5501.2023.04.001 . Cited in this article [1]

[9]

Hogan

, Dossier

, Kwon

, et al. Effect of different rituximab regimens on B cell depletion and time to relapse in children with steroid-dependent nephrotic syndrome[J]. Pediatr Nephrol, 2019, 34(2): 253-259. DOI: 10.1007/s00467-018-4052-x .

https://www.ncbi.nlm.nih.gov/pubmed/30109447

Cited in this article [3]

[10]	黄敏, 王晓霞, 王晓春, 等. 极低剂量利妥昔单抗治疗原发性难治性肾病综合征的疗效及对肾功能、免疫球蛋白、Toll样受体的影响[J]. 临床肾脏病杂志, 2022, 22(10): 827-833. DOI: 10.3969/j.issn.1671-2390.2022.10.006 . Cited in this article [2]

[11]	朱颖, 吴琳, 王云, 等. 低剂量利妥昔单抗治疗儿童肾病综合征疗效及安全性的前瞻性随机对照研究[J]. 中国当代儿科杂志, 2023, 25(6): 606-611. PMCID: PMC10321428. DOI: 10.7499/j.issn.1008-8830.2301026 . https://www.ncbi.nlm.nih.gov/pubmed/37382130 Cited in this article [4]

[12]	Benz K, Dötsch J, Rascher W, et al. Change of the course of steroid-dependent nephrotic syndrome after rituximab therapy[J]. Pediatr Nephrol, 2004, 19(7): 794-797. DOI: 10.1007/s00467-004-1434-z . https://www.ncbi.nlm.nih.gov/pubmed/15071769 Cited in this article [1]

[13]

Zhang

, Jin

, Li

, et al. Successful treatment of new-onset pediatric nephrotic syndrome with rituximab as a first-line therapy[J]. Kidney Int Rep, 2022, 7(12): 2750-2751. PMCID: PMC9727513. DOI: 10.1016/j.ekir.2022.10.016 .

https://www.ncbi.nlm.nih.gov/pubmed/36506238

Cited in this article [1]

[14]	Liu J, Deng F, Wang X, et al. Early rituximab as an add-on therapy in children with the initial episode of nephrotic syndrome[J]. Kidney Int Rep, 2024, 9(5): 1220-1227. PMCID: PMC11069012. DOI: 10.1016/j.ekir.2024.02.1395 . https://www.ncbi.nlm.nih.gov/pubmed/38707815 Cited in this article [1]

[15]	Bagga A, Sinha A, Moudgil A. Rituximab in patients with the steroid-resistant nephrotic syndrome[J]. N Engl J Med, 2007, 356(26): 2751-2752. DOI: 10.1056/NEJMc063706 . https://www.ncbi.nlm.nih.gov/pubmed/17596616 Cited in this article [1]

[16]

Yokota

, Kamei

, Fujinaga

, et al. Efficacy of rituximab and risk factors for poor prognosis in patients with childhood-onset steroid-resistant nephrotic syndrome: a multicenter study[J]. Pediatr Nephrol, 2024, 39(10): 2979-2988. DOI: 10.1007/s00467-024-06422-5 .

https://www.ncbi.nlm.nih.gov/pubmed/38834892

Cited in this article [1]

[17]

Gomes

, Mosca

, Bastos-Gomes

, et al. Rituximab therapy for childhood onset idiopathic nephrotic syndrome: experience of a Portuguese tertiary center[J]. J Bras Nefrol, 2023, 45(3): 326-334. PMCID: PMC10697169. DOI: 10.1590/2175-8239-JBN-2022-0056en .

https://www.ncbi.nlm.nih.gov/pubmed/36259942

Cited in this article [2]

[18]	Chan EY, Yap DY, Colucci M, et al. Use of rituximab in childhood idiopathic nephrotic syndrome[J]. Clin J Am Soc Nephrol, 2023, 18(4): 533-548. PMCID: PMC10103321. DOI: 10.2215/cjn.08570722 . https://www.ncbi.nlm.nih.gov/pubmed/36456193 Cited in this article [1]

[19]	Sinha A, Mathew G, Arushi A, et al. Sequential rituximab therapy sustains remission of nephrotic syndrome but carries high risk of adverse effects[J]. Nephrol Dial Transplant, 2023, 38(4): 939-949. DOI: 10.1093/ndt/gfac228 . https://www.ncbi.nlm.nih.gov/pubmed/36071552 Cited in this article [1]

[20]

Bonanni

, Calatroni

, D'Alessandro

, et al. Adverse events linked with the use of chimeric and humanized anti-CD20 antibodies in children with idiopathic nephrotic syndrome[J]. Br J Clin Pharmacol, 2018, 84(6): 1238-1249. PMCID: PMC5980330. DOI: 10.1111/bcp.13548 .

https://www.ncbi.nlm.nih.gov/pubmed/29436729

Cited in this article [1]

[21]	Choi N, Min J, Kim JH, et al. Efficacy and safety of long-term repeated use of rituximab in pediatric patients with nephrotic syndrome[J]. Pediatr Nephrol, 2024, 39(3): 771-780. DOI: 10.1007/s00467-023-06124-4 . https://www.ncbi.nlm.nih.gov/pubmed/37682369 Cited in this article [2]

[22]

Chan

, Yu

ELM

, Angeletti

, et al. Long-Term efficacy and safety of repeated rituximab to maintain remission in idiopathic childhood nephrotic syndrome: an international study[J]. J Am Soc Nephrol, 2022, 33(6): 1193-1207. PMCID: PMC9161790. DOI: 10.1681/asn.2021111472 .

https://www.ncbi.nlm.nih.gov/pubmed/35354600

Cited in this article [2]